ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aeglea Receives FDA Rare Pediatric Disease Designation for Homocystinuria Treatment
December 22, 2020Aeglea BioTherapeutics announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ACN00177 for the treatment of Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine ... -
Aeglea BioTherapeutics Updates Phase I/II Trial Data
March 14, 2018Aeglea Biotherapeutics, headquartered in Austin, Texas, announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.
Pharma Sources Insight January 2025
